ezetimibe has been researched along with Infusion Site Adverse Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, SA; Naz, A; Qamar Masood, M; Shah, R | 1 |
| Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF | 1 |
1 review(s) available for ezetimibe and Infusion Site Adverse Event
| Article | Year |
|---|---|
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Anticholesteremic Agents; Apolipoproteins B; Aspartate Aminotransferases; Bilirubin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injection Site Reaction; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; RNA, Small Interfering; Stroke | 2020 |
1 trial(s) available for ezetimibe and Infusion Site Adverse Event
| Article | Year |
|---|---|
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Combined Modality Therapy; Diet Therapy; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Injection Site Reaction; Male; Middle Aged; PCSK9 Inhibitors; Treatment Outcome | 2016 |